CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.78
−1.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 125.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | 125.0K |
| Operating Expenses | |||||
| R&D Expense | 49.1M | 30.5M | 19.3M | 24.5M | 20.8M |
| SG&A Expense | 22.9M | 17.8M | 14.1M | 13.9M | 14.1M |
| General & Admin Expense | 22.9M | 17.8M | 14.1M | 13.9M | 14.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (48.0K) |
| Total Operating Expenses | 72.0M | 48.3M | 33.4M | 38.4M | 34.8M |
| Cost and Expenses | 72.0M | 48.3M | 33.4M | 38.4M | 34.8M |
| Operating Income (EBIT) | (72.0M) | (48.3M) | (33.4M) | (38.4M) | (34.7M) |
| Non-Operating | |||||
| Interest Income | 5.0M | 3.9M | 1.1M | 2.1M | 1.2M |
| Interest Expense | 4.7M | 2.1M | 2.1M | 2.6M | 1.7M |
| Net Interest Income | 333.0K | 1.8M | (1.0M) | (514.0K) | (490.0K) |
| Other Non-Op Income/Expense | (16.5M) | 10.1M | (21.8M) | 452.0K | 15.9M |
| Non-Operating Income (excl Interest) | 11.8M | (12.2M) | 19.7M | (3.0M) | (17.6M) |
| EBT (Pre-Tax Income) | (88.5M) | (38.2M) | (55.2M) | (37.9M) | (18.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (88.5M) | (38.2M) | (55.2M) | (37.9M) | (18.8M) |
| Earnings from Cont. Ops | (88.5M) | (38.2M) | (55.2M) | (37.9M) | (18.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (88.5M) | (38.2M) | (55.2M) | (37.9M) | (18.8M) |
| Per Share | |||||
| Basic EPS | ($1.41) | ($0.72) | ($1.74) | ($1.31) | ($0.10) |
| Diluted EPS | ($1.41) | ($0.72) | ($1.74) | ($1.31) | ($0.10) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 74.1M | 53.0M | 31.7M | 28.9M | 28.8M |
| Diluted Shares Outstanding | 74.1M | 53.0M | 31.7M | 28.9M | 28.8M |
| Profitability Metrics | |||||
| EBITDA | (83.0M) | (35.2M) | (52.1M) | (34.4M) | (16.3M) |
| D&A | 827.0K | 845.0K | 990.0K | 960.0K | 778.0K |
| EBIT | (83.8M) | (36.1M) | (53.1M) | (35.3M) | (17.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026